MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, XAGE had -$441,971 decrease in cash & cash equivalents over the period. -$1,447,980 in free cash flow.

Cash Flow Overview

Change in Cash
-$441,971
Free Cash flow
-$1,447,980

Unit: Dollar
Cash Flow
2025-09-30
2025-06-30
Net loss from continuing operations
-1,429,755 -3,392,305
Loss from discontinued operations, net of tax
-0
Stock-based compensation
189,926 309,152
Depreciation and amortization of intangible assets
16,268 46,136
Amortization of right of use assets
21,379 93,174
Loss on forward purchase agreement
-0
Change in fair value of earnout liabilities
-86,104 29,630
Inventory write-down
47,082 -
Accounts receivable and other current assets
-7,974 -26,155
Inventory
-112,184 -222,210
Prepaid expenses
-87,421 -321,096
Accounts payable
-455,757 258,791
Accrued expenses and other liabilities
77,816 592,530
Amortization of debt discount
-0
Lease liability
-22,190 -95,712
Net cash used in operating activities
-1,433,756 -1,589,143
Cash paid for offering costs
-15,000
Cash paid for elevai acquisition transaction costs
0 150,000
Purchases of property and equipment
14,224 -
Proceeds from issuance of loans
-0
Net cash used in investing activities
776 -165,000
Proceeds from issuance of common stock, net of costs
86,314 3,397,476
Proceeds from exercise of common stock warrants
1,000,000 -
Repayment of loans
95,305 249,273
Net cash provided by financing activities
991,009 3,148,203
Net increase (decrease) in cash
-441,971 1,394,060
Cash and cash equivalents at beginning of period
157,139 -
Cash and cash equivalents at end of period
1,109,228 -
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Longevity Health Holdings, Inc. (XAGE)

Longevity Health Holdings, Inc. (XAGE)